The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Open accessAbstract
New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway plays pivotal roles in regulating tumor angiogenesis. VEGF as a therapeutic target has been validated in various types of human cancers. Different agents including antibodies, aptamers, peptides, and small molecules have been extensively investigated to block VEGF and its pro-angiogenic functions. Some of these agents have been approved by FDA and some are currently in clinical trials. Combination therapies are also being pursued for better tumor control. By providing comprehensive real-time information, molecular imaging of VEGF pathway may accelerate the drug development process. Moreover, the imaging will be of great help for patient stratification and therapeutic effect monitoring, which will promote effective personalized molecular cancer therapy. This review summarizes the current status of tumor therapeutic agents targeting to VEGF and the applications of VEGF related molecular imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
Massoud, T. F., & Gambhir, S. S. (2003) · Genes & Development · doi:10.1101/gad.1047403 · Cited by 2,216
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Basement membranes: structure, assembly and role in tumour angiogenesis
Kalluri, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1094 · Cited by 1,748
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., & Heldin, C. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47116-5 · Cited by 1,656
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., & Kolesnick, R. (2003) · Science · doi:10.1126/science.1082504 · Cited by 1,593
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. T. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2175 · Cited by 1,405
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Definition of Two Angiogenic Pathways by Distinct α v Integrins
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., & Cheresh, D. A. (1995) · Science · doi:10.1126/science.270.5241.1500 · Cited by 1,321
Takahashi, Y., Kitadai, Y., Bucana, C. D., Cleary, K. R., & Ellis, L. M. (1995) · PubMed · Cited by 1,265
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Park, J. E., Keller, G. A., & Ferrara, N. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.12.1317 · Cited by 1,122
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Hlatky, L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.12.883 · Cited by 787
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O'Brien, S. M., Davis, R. B., Gowen, L. C., et al. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 775
Nalluri, S. R., Chu, D., Keresztes, R., Zhu, X., & Wu, S. (2008) · JAMA · doi:10.1001/jama.2008.656 · Cited by 771
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Yuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719
Prewett, M. C., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K. D., Overholser, J. C., Hooper, A. T., Pytowski, B., Witte, L., et al. (1999) · PubMed · Cited by 713
Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries
Siekmann, A. F., & Lawson, N. D. (2007) · Nature · doi:10.1038/nature05577 · Cited by 687
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Nör, J. E., Christensen, J., Mooney, D. J., & Polverini, P. J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65284-4 · Cited by 641
Gerber, H.-P., & Ferrara, N. (2005) · Cancer Research · doi:10.1158/0008-5472.671.65.3 · Cited by 626
Axis of evil: molecular mechanisms of cancer metastasis
Bogenrieder, T., & Herlyn, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206757 · Cited by 593
Tumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1971 · Cited by 575
Fujio, Y., & Walsh, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16349 · Cited by 553
(2002) · PubMed · Cited by 550
Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O'Bryant, C., Chow, L. Q. M., Serkova, N. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7537 · Cited by 549
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
De Falco, E., Porcelli, D., Torella, A. R., Straino, S., Iachininoto, M. G., Orlandi, A., Truffa, S., Biglioli, P., Napolitano, M., Capogrossi, M. C., et al. (2004) · Blood · doi:10.1182/blood-2003-12-4423 · Cited by 521
Wedam, S. B., Low, J. A., Yang, S. X., Chow, C. K., Choyke, P., Danforth, D., Hewitt, S. M., Berman, A., Steinberg, S. M., Liewehr, D. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4645 · Cited by 518
VEGF-A splicing: the key to anti-angiogenic therapeutics?
Harper, S. J., & Bates, D. O. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2505 · Cited by 514
Benjamin, L. E., & Keshet, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8761 · Cited by 506
Bachelder, R. E., Crago, A. M., Chung, J., Wendt, M. A., Shaw, L. M., Robinson, G. S., & Mercurio, A. M. (2001) · PubMed · Cited by 487
Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor
Wiesmann, C., Fuh, G., Christinger, H. W., Eigenbrot, C., Wells, J. A., & de Vos, A. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80456-0 · Cited by 486
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., & Jayson, G. C. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603515 · Cited by 484
Contribution of bone marrow–derived endothelial cells to human tumor vasculature
Peters, B. A., Diaz, L. A., Polyak, K., Meszler, L., Romans, K., Guinan, E. C., Antin, J. H., Myerson, D., Hamilton, S. R., Vogelstein, B., et al. (2005) · Nature Medicine · doi:10.1038/nm1200 · Cited by 482
Tumor-Associated Endothelial Cells with Cytogenetic Abnormalities
Hida, K., Hida, Y., Amin, D. N., Flint, A. F., Panigrahy, D., Morton, C. C., & Klagsbrun, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1567 · Cited by 470
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.861 · Cited by 469
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E., & Carbone, D. P. (1999) · PubMed · Cited by 459
Echocardiographic Destruction of Albumin Microbubbles Directs Gene Delivery to the Myocardium
Shohet, R. V., Chen, S., Zhou, Y.-T., Wang, Z., Meidell, R. S., Unger, R. H., & Grayburn, P. A. (2000) · Circulation · doi:10.1161/01.cir.101.22.2554 · Cited by 446
Genes that Distinguish Physiological and Pathological Angiogenesis
Seaman, S., Stevens, J., Yang, M. Y., Logsdon, D., Graff-Cherry, C., & St. Croix, B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.017 · Cited by 419
Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding
Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., & Miller, D. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26369 · Cited by 407
Ogawa, S., Oku, A., Sawano, A., Yamaguchi, S., Yazaki, Y., & Shibuya, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31273 · Cited by 406
Purhonen, S., Palm, J., Rossi, D., Kaskenpää, N., Rajantie, I., Ylä-Herttuala, S., Alitalo, K., Weissman, I. L., & Salven, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710516105 · Cited by 399
Baffert, F., Le, T., Sennino, B., Thurston, G., Kuo, C. J., Hu-Lowe, D., & McDonald, D. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00616.2005 · Cited by 374
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 367
Zhang, C., Jugold, M., Woenne, E. C., Lammers, T., Morgenstern, B., Mueller, M. M., Zentgraf, H., Bock, M., Eisenhut, M., Semmler, W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1668 · Cited by 336
Geng, L., Donnelly, E. F., McMahon, G., Lin, P. C., Sierra‐Rivera, E., Oshinka, H., & Hallahan, D. E. (2001) · PubMed · Cited by 334
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., de Bruijn, E. A., & van Oosterom, A. T. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601005 · Cited by 334
Complex role of matrix metalloproteinases in angiogenesis
Sang, Q. X. A. (1998) · Cell Research · doi:10.1038/cr.1998.17 · Cited by 332
Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001) · PubMed · Cited by 331
Ciardiello, F., Caputo, R., Damiano, V., Caputo, R., Troiani, T., Vitagliano, D., Carlomagno, F., Veneziani, B. M., Fontanini, G., Bianco, A. R., et al. (2003) · PubMed · Cited by 328
In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., Brouwers, A. H., van Dongen, G. A., Perk, L. R., & Lub-de Hooge, M. N. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.041301 · Cited by 313
The role of VEGF in the regulation of physiological and pathological angiogenesis
Ferrara, N. (2005) · Mechanisms of Angiogenesis · doi:10.1007/3-7643-7311-3_15 · Cited by 312
Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Müller, M., Wood, J. M., Martiny‐Baron, G., Unger, C., & Marmé, D. (2000) · PubMed · Cited by 308
Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus
Lyttle, D. J., Fraser, K. M., Fleming, S. B., Mercer, A. A., & Robinson, A. J. (1994) · Journal of Virology · doi:10.1128/jvi.68.1.84-92.1994 · Cited by 303
Willmann, J. K., Paulmurugan, R., Chen, K., Gheysens, O., Rodriguez-Porcel, M., Lutz, A. M., Chen, I. Y., Chen, X., & Gambhir, S. S. (2008) · Radiology · doi:10.1148/radiol.2462070536 · Cited by 301
Self-citationLi, J.-L., Sainson, R. C. A., Shi, W., Leek, R., Harrington, L. S., Preusser, M., Biswas, S., Turley, H., Heikamp, E., Hainfellner, J. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0969 · Cited by 299
Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer
Curiel, T. J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M., Wei, S., Zou, L., Kryczek, I., Hoyle, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1272 · Cited by 297
Developing aptamers into therapeutics
White, R. R., Sullenger, B. A., & Rusconi, C. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11325 · Cited by 295
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Hutson, T. E., Davis, I. D., Machiels, J.-P. H., De Souza, P. L., Rottey, S., Hong, B.-F., Epstein, R. J., Baker, K. L., McCann, L., Crofts, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6994 · Cited by 295
Tumor angiogenesis and tissue factor
Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0296-167 · Cited by 293
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2130 · Cited by 290
Nissen, L. J., Cao, R., Hedlund, E.-M., Wang, Z., Zhao, X., Wetterskog, D., Funa, K., Bråkenhielm, E., & Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32479 · Cited by 290
Kanno, S., Oda, N., Abe, M., Terai, Y., Ito, M., Shitara, K., Tabayashi, K., Shibuya, M., & Sato, Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203533 · Cited by 285
Green, L. S., Jellinek, D., Bell, C., Beebe, L. A., Feistner, B. D., Gill, S. C., Jucker, F. M., & Janjić, N. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90032-2 · Cited by 284
Dias, S., Hattori, K., Heissig, B., Zhu, Z., Wu, Y., Witte, L., Hicklin, D. J., Tateno, M., Bohlen, P., Moore, M. A. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191117498 · Cited by 268
Barrett, T., Brechbiel, M., Bernardo, M., & Choyke, P. L. (2007) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20991 · Cited by 266
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
PET of vascular endothelial growth factor receptor expression.
Cai, W., Chen, K., Mohamedali, K. A., Cao, Q., Gambhir, S. S., Rosenblum, M. G., & Chen, X. S. (2006) · PubMed · Cited by 262
Self-citationSchueneman, A. J., Himmelfarb, E. A., Geng, L., Tan, J., Donnelly, E. F., Mendel, D. B., McMahon, G., & Hallahan, D. E. (2003) · PubMed · Cited by 259
Lin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 255
Molecular and functional diversity of vascular endothelial growth factors
Yamazaki, Y., & Morita, T. (2006) · Molecular Diversity · doi:10.1007/s11030-006-9027-3 · Cited by 255
The role of the VEGF-C/VEGFR-3 axis in cancer progression
Su, J.-L., Yen, C.-J., Chen, P.-S., Chuang, S.-E., Hong, C.-C., Kuo, I.-H., Chen, H.-Y., Hung, M.-C., & Kuo, M.-L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603487 · Cited by 252
Rock, E. P., Goodman, V., Jiang, J. X., Mahjoob, K., Verbois, S. L., Morse, D., Dagher, R., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-107 · Cited by 247
Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature
Korpanty, G., Carbon, J. G., Grayburn, P. A., Fleming, J. B., & Brekken, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1313 · Cited by 245
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
Backer, M. V., Levashova, Z., Patel, V., Jehning, B. T., Claffey, K., Blankenberg, F. G., & Backer, J. M. (2007) · Nature Medicine · doi:10.1038/nm1522 · Cited by 243
Lee, J.-H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y.-S., Shima, D. T., Pardi, A., & Jucker, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509069102 · Cited by 242
First steps of tumor-related angiogenesis.
Paku, S., & Paweletz, N. (1991) · PubMed · Cited by 238
Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 Antagonism
Cai, W., & Chen, X. (2006) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152006778226530 · Cited by 235
Self-citationGirvan, A. C., Teng, Y., Casson, L. K., Thomas, S. D., Jüliger, S., Ball, M. W., Klein, J. B., Pierce, W. M., Barve, S. S., & Bates, P. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0361 · Cited by 235
Lockhart, A. C., Rothenberg, M. L., Dupont, J., Cooper, W., Chevalier, P., Sternas, L., Buzenet, G., Koehler, E., Sosman, J. A., Schwartz, L. H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9237 · Cited by 232
Predicting benefit from anti-angiogenic agents in malignancy
Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228
Thomas, A. L., Morgan, B., Horsfield, M. A., Higginson, A., Kay, A., Lee, L., Masson, E., Puccio-Pick, M., Laurent, D., & Steward, W. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.034 · Cited by 228
Huang, J., Frischer, J. S., Serur, A., Kadenhe, A., Yokoi, A., McCrudden, K. W., New, T., O'Toole, K., Zabski, S., Rudge, J. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432908100 · Cited by 227
Mannavola, D., Coco, P., Vannucchi, G., Bertuelli, R., Carletto, M., Casali, P. G., Beck-Peccoz, P., & Fugazzola, L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0586 · Cited by 227
Ratain, M. J., & Eckhardt, S. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.960 · Cited by 227
Varey, A. H. R., Rennel, E. S., Qiu, Y., Bevan, H. S., Perrin, R. M., Raffy, S., Dixon, A. R., Paraskeva, C., Zaccheo, O., Hassan, A. B., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604308 · Cited by 226
Neuropilins in physiological and pathological angiogenesis
Staton, C., Kumar, I., Reed, M., & Brown, N. (2007) · The Journal of Pathology · doi:10.1002/path.2182 · Cited by 224
Iwamoto, F. M., Lamborn, K. R., Robins, H. I., Mehta, M. P., Chang, S. M., Butowski, N. A., DeAngelis, L. M., Abrey, L. E., Zhang, W.-T., Prados, M. D., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq025 · Cited by 223
Perrin, R. M., Konopatskaya, O., Qiu, Y., Harper, S., Bates, D. O., & Churchill, A. J. (2005) · Diabetologia · doi:10.1007/s00125-005-1951-8 · Cited by 217
Yuan, A., Yu, C.-J., Kuo, S.-H., Chen, W.-J., Lin, F.-Y., Luh, K.-T., Yang, P.-C., & Lee, Y.-C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.432 · Cited by 207
Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors.
Tessler, S., Rockwell, P., Hicklin, D., Cohen, T., Levi, B. Z., Witte, L., Lemischka, I. R., & Neufeld, G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99896-0 · Cited by 194
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Curwen, J., Hennequin, L. F., Thomas, A., Stokes, E. S. E., Curry, B. J., Richmond, G., et al. (2000) · PubMed · Cited by 192
Bruns, C. J., Liu, W., Davis, D. W., Shaheen, R. M., McConkey, D. J., Wilson, M. R., Bucana, C. D., Hicklin, D. J., & Ellis, L. M. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<488::aid-cncr3>3.0.co;2-x · Cited by 189
Hlatky, L., Tsionou, C., Hahnfeldt, P., & Coleman, C. N. (1994) · PubMed · Cited by 187
Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension
Izzedine, H., Rixe, O., Billemont, B., Baumelou, A., & Deray, G. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.04.025 · Cited by 186
Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor
Jellinek, D., Green, L. S., Bell, C., & Janjic, N. (1994) · Biochemistry · doi:10.1021/bi00200a028 · Cited by 184
Lu, D., Shen, J., Vil, M. D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., & Zhu, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307742200 · Cited by 183
Wlotzka, B., Leva, S., Eschgfäller, B., Burmeister, J., Kleinjung, F., Kaduk, C., Muhn, P., Hess-Stumpp, H., & Klussmann, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132067399 · Cited by 183
Fricke, I., Mirza, N., Dupont, J., Lockhart, C., Jackson, A., Lee, J.-H., Sosman, J. A., & Gabrilovich, D. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0409 · Cited by 182
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature
Backer, M. V., Gaynutdinov, T. I., Patel, V., Bandyopadhyaya, A. K., Thirumamagal, B. T. S., Tjarks, W., Barth, R. F., Claffey, K., & Backer, J. M. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0161 · Cited by 180
In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease
Negrin, R. S., & Contag, C. H. (2006) · Nature Reviews Immunology · doi:10.1038/nri1879 · Cited by 172
Landgren, E., Schiller, P., Cao, Y., & Claesson-Welsh, L. (1998) · Oncogene · doi:10.1038/sj.onc.1201545 · Cited by 168
Hurwitz, H. (2004) · Clinical Colorectal Cancer · doi:10.3816/ccc.2004.s.010 · Cited by 165
Inhibition of DNA Replication and Induction of S Phase Cell Cycle Arrest by G-rich Oligonucleotides
Xu, X., Hamhouyia, F., Thomas, S. D., Burke, T. J., Girvan, A. C., McGregor, W. G., Trent, J. O., Miller, D. M., & Bates, P. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104446200 · Cited by 165
Tumor Angiogenesis: Iris Neovascularization at a Distance From Experimental Intraocular Tumors2
Gimbrone, M. A., Leapman, S. B., Cotran, R. S., & Folkman, J. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/50.1.219 · Cited by 165
Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T., & Jaffe, R. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64467-7 · Cited by 161
Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver
Gray, M. J., Van Buren, G., Dallas, N. A., Xia, L., Wang, X., Yang, A. D., Somcio, R. J., Lin, Y. G., Lim, S., Fan, F., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm279 · Cited by 158
Molecular mechanisms of tumor vascularization
Auguste, P., Lemière, S., Larrieu-Lahargue, F., & Bikfalvi, A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.11.006 · Cited by 156
de Smidt, P. C., Doan, T. L., Falco, S. D., et al. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.17.4695 · Cited by 155
Vascular endothelial growth factor expression is increased in renal cell carcinoma.
Nicol, D. L., Hii, S.-I., Walsh, M. D., Teh, B. T., Thompson, L. C., Kennett, C., & Gotley, D. C. (1997) · PubMed · Cited by 150
VPF/VEGF and the angiogenic response
Dvorak, H. F. (2000) · Seminars in Perinatology · doi:10.1016/s0146-0005(00)80061-0 · Cited by 149
Yamazaki, Y., Takani, K., Atoda, H., & Morita, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300454200 · Cited by 148
MRI for assessing antivascular cancer treatments
Padhani, A. R. (2003) · British Journal of Radiology · doi:10.1259/bjr/15334380 · Cited by 142
Lü, D., Jimenez, X., Zhang, H., Böhlen, P., Witte, L., & Zhu, Z. (2001) · International Journal of Cancer · doi:10.1002/ijc.1634 · Cited by 136
Laird, A., Christensen, J. G., Li, G., Carver, J., Smith, K., Xin, X., Moss, K. G., Louie, S. G., Mendel, D. B., & Cherrington, J. M. (2002) · The FASEB Journal · doi:10.1096/fj.01-0700com · Cited by 131
The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice
Rennel, E. S., Waine, E., Guan, H., Schüler, Y., Leenders, W. P. J., Woolard, J., Sugiono, M., Gillatt, D. A., Kleinerman, E. S., Bates, D. O., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604309 · Cited by 131
UNDERINER, T. L., Ruggeri, B., & Gingrich, D. E. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455756 · Cited by 127
Hu, L., Hofmann, J., Holash, J. A., Yancopoulos, G. D., Sood, A. K., & Jaffe, R. B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0910 · Cited by 127
Takahashi, H., Hattori, S., Iwamatsu, A., Takizawa, H., & Shibuya, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403687200 · Cited by 123
The joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets
Eaton, B. E. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80103-2 · Cited by 123
Fukasawa, M., & Korc, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0820 · Cited by 122
Dayton, P. A., Pearson, D., Clark, J., Simon, S. I., Schumann, P. A., Zutshi, R., Matsunaga, T. O., & Ferrara, K. W. (2004) · Molecular Imaging · doi:10.1162/1535350041464883 · Cited by 119
PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models
Niu, G., Li, Z., Xie, J., Le, Q., & Chen, X. S. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.061820 · Cited by 118
Self-citationA new PET tracer specific for vascular endothelial growth factor receptor 2
Wang, H., Cai, W., Chen, K., Li, Z., Kashefi, A., He, L., & Chen, X. S. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0524-0 · Cited by 114
Self-citationPazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Sloan, B., & Scheinfeld, N. S. (2008) · PubMed · Cited by 112
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer
Fernando, N., & Hurwitz, H. I. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70024-4 · Cited by 111
Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro
Bell, C., Lynam, E. B., Landfair, D. J., Janjić, N., & Wiles, M. E. (1999) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-999-0064-y · Cited by 109
Sun, J., Wang, D.-A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M. A., Baldini, L., Coppola, D., Hamilton, A. D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208391 · Cited by 108
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
Summers, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0250 · Cited by 106
Fox, W. D., Higgins, B., Maiese, K., Drobnjak, M., Cordon‐Cardo, C., Scher, H. I., & Agus, D. B. (2002) · PubMed · Cited by 105
Tumor angiogenesis and molecular targets for therapy
Cao, Y. (2009) · Frontiers in bioscience · doi:10.2741/3504 · Cited by 104
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis
Huang, J., Soffer, S. Z., Kim, E. S., McCrudden, K. W., Huang, J. T., New, T. N., Manley, C. A., Middlesworth, W., O’Toole, K., Yamashiro, D. J., et al. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.36.2.1 · Cited by 101
Ikezoe, T., Nishioka, C., Tasaka, T., Yang, Y., Komatsu, N., Togitani, K., Koeffler, H. P., & Taguchi, H. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0071 · Cited by 101
Antiangiogenic drugs in ovarian cancer
Kumaran, G., Jayson, G. C., & Clamp, A. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604767 · Cited by 99
Xu, L., Cochran, D., Tong, R. T., Winkler, F., Kashiwagi, S., Jain, R. K., & Fukumura, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-3085 · Cited by 89
Selection of DNA aptamers against VEGF165 using a protein competitor and the aptamer blotting method
Hasegawa, H., Sode, K., & Ikebukuro, K. (2008) · Biotechnology Letters · doi:10.1007/s10529-007-9629-6 · Cited by 82
Pegaptanib for the treatment of age-related macular degeneration
Zhou, B., & Wang, B. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.02.010 · Cited by 81
Angiogenic factors as tumor markers
Nguyen, M. T. N. (1997) · Investigational New Drugs · doi:10.1023/a:1005766511385 · Cited by 80
Recombinant human VEGF165b protein is an effective anti-cancer agent in mice
Rennel, E., Hamdollah‐Zadeh, M., Wheatley, E. R., Magnussen, A., Schüler, Y., Kelly, S., Finucane, C. M., Ellison, D. H., Suarez, S., Ballmer‐Hofer, K., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.027 · Cited by 80
Kamrava, M. R., Bernstein, M. B., Camphausen, K. A., & Hodge, J. W. (2009) · Molecular BioSystems · doi:10.1039/b911313b · Cited by 78
Therapeutic Targets of Multiple Angiogenic Factors for the Treatment of Cancer and Metastasis
Cao, Y., & Liu, Q. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97009-2 · Cited by 76
Measuring tumour vascular response to antivascular and antiangiogenic drugs
Tozer, G. M. (2003) · British Journal of Radiology · doi:10.1259/bjr/30165281 · Cited by 74
Looking for a good endothelial address
Folkman, J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00038-7 · Cited by 68
Assessment of angiogenesis: implications for ultrasound imaging
Forsberg, F., Ro, R. J., Potoczek, M., Liu, J., Merritt, C. R. B., James, K. M., Dicker, A. P., & Nazarian, L. N. (2003) · Ultrasonics · doi:10.1016/j.ultras.2003.12.026 · Cited by 66
Dallas, N. A., Fan, F., Gray, M. J., Buren, G. V., Lim, S. J., Xia, L., & Ellis, L. M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9070-2 · Cited by 62
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer
Fernando, N. H., & Hurwitz, H. I. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00124-6 · Cited by 62
Qiu, Y., Bevan, H. S., Weeraperuma, S., Wratting, D., Murphy, D., Neal, C. R., Bates, D. O., & Harper, S. J. (2007) · The FASEB Journal · doi:10.1096/fj.07-9718com · Cited by 59
Schomber, T., Kopfstein, L., Djonov, V., Albrecht, I., Baeriswyl, V., Strittmatter, K., & Christofori, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1034 · Cited by 52
TNP-470/minocycline/cytotoxic therapy: A systems approach to cancer therapy
Teicher, B. A., Emi, Y., Kakeji, Y., & Northey, D. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00380-2 · Cited by 50
Cited by
Cell death-based treatment of lung adenocarcinoma
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0063-y · Cited by 768
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
A snapshot of the PD-1/PD-L1 pathway
Ghosh, C., Luong, G., & Sun, Y. (2021) · Journal of Cancer · doi:10.7150/jca.57334 · Cited by 292
Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases
Fallah, A., Sadeghinia, A., Kahroba, H., Samadi, A., Heidari, H. R., Bradaran, B., Zeinali, S., & Molavi, O. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.022 · Cited by 259
Metadata
- Authors
- Niu, G., & Chen, X.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-08-01
- Volume
- 11
- Issue
- 8
- Pages
- 1000-1017
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2055242813
- Cited by
- 451
- References
- 215
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.